MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31.

Income Overview

Net Income
-$47,594,000
EPS
-$0.42
Unit: Dollar

Income Statement
2026-03-31
2025-12-31
2025-09-30
Revenue
0 0* 0
Research and development
31,454,000 39,811,000* 34,068,000
General and administrative
17,057,000 31,448,000* 18,351,000
Restructuring
-3,747,000* -172,000
Total operating expenses
48,511,000 75,006,000* 52,247,000
Loss from operations
-48,511,000 -75,006,000* -52,247,000
Interest expense
473,000 472,000* 473,000
Interest and other income, net
161,000 1,091,000* 709,000
Accretion of discount on investments, net
1,229,000 2,260,000* 1,679,000
Net loss
-47,594,000 -72,127,000 -50,332,000
Basic EPS
-0.42 -0.652 -0.45
Diluted EPS
-0.42 -0.652 -0.45
Basic Average Shares
112,134,059 110,676,404 111,571,136
Diluted Average Shares
112,134,059 110,676,404 111,571,136
Unit: Dollar. Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Net loss-$47,594,000 Accretion of discount oninvestments, net$1,229,000 Interest and otherincome, net$161,000 Loss from operations-$48,511,000 Interest expense$473,000 Total operatingexpenses$48,511,000 Research and development$31,454,000 General andadministrative$17,057,000

ROCKET PHARMACEUTICALS, INC. (RCKTW)

ROCKET PHARMACEUTICALS, INC. (RCKTW)